ELZONRIS

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, Ireland, Lithuania, Poland.

Active ingredients

The drug ELZONRIS contains one active pharmaceutical ingredient (API):

1	Tagraxofusp UNII 8ZHS5657EH - TAGRAXOFUSP
	Tagraxofusp is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
	Read more about Tagraxofusp

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELZONRIS Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX67		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX67

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1836479
LT	Valstybinė vaistų kontrolės tarnyba	1091753
PL	Rejestru Produktów Leczniczych	100446916
US	FDA, National Drug Code	72187-0401